Veronica Shubayev;Sanford Burnham Prebys Medical Discovery Institute
发明人:
Veronica Shubayev,Alex Strongin,Albert G. Remacle
申请号：
US16651114
公开号：
US20200225244A1
申请日:
2018.09.25
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Disclosed are compositions, kits, and methods for detecting and assessing demyelinating diseases and conditions, neuropathic pain related to demyelinating diseases and conditions, selecting subjects for treatment with a ligand for voltage-gated Ca2+-channel α2δ1 (CACNA2D1 ligand), and selecting subjects to not be treated with a CACNA2D1 ligand. It has been discovered that the presence of antibodies to a proteolytic fragment of myelin basic protein (myelin basic protein-derived peptide (MBP84-104)) in subjects suffering from neuropathic pain indicates that (1) the subject is suffering from a demyelinating disease or condition and (2) that such subjects are more effectively treated with a CACNA2D1 ligand such as gabapentin or pregabalin as distinct from treatment with other pain relievers such as COX inhibitors (such as ketorolac), sodium channel blockers (such as lidocaine), and NMDA antagonists (such as MK801).
